Cosmos Health Secures 5-Year, 385K-Unit CERTORUN Contract, Inaugurates New Production Line
COSM is trading near its 52-week low of $0.211 (13% above the low) on elevated volume (2.5× avg).
Summary
Cosmos Health's subsidiary, Cana Laboratories, secured a new five-year contract to manufacture 385,000 units of CERTORUN, an antidepressant, for Provident Pharmaceuticals. This agreement, which includes the inauguration of a new capsule production line, will generate 77,000 units annually. This positive news provides a much-needed source of high-margin, recurring revenue and cash flow visibility for Cosmos Health. The company has recently reported a 'going concern' warning, widened losses, and increased cash burn in its latest SEC filings, alongside plans for significant share dilution.
At the time of this announcement, COSM was trading at $0.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.3M. The 52-week trading range was $0.21 to $1.32. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.